Biotech Values

[pollyvonwog]

It certainly doesn't make any sense whatsoever UNLESS these two numbers are much closer to each other as a net payment to Momenta. The people here wouldn't agree at this point.

I think that point is utterly absurd.

In regards to the m-enox deal, CW said at the UBS conference that they were in a much better negotiation position with the 2006 copax agreement and the terms reflect that sentiment. When enox was signed, MNTA was a brand new company looking for validation for their platform. I would imagine that NVS had doubts about MNTA's technology in 2003 and so a deal was constructed with those doubts in mind. In 2006, it was clear that their technology was unique and quite valuable and gave MNTA the edge in negotiating.